Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02652091 · ClinicalTrials.gov registry record
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 146
- Enrollment target
NCT02652091 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 146 participants.
The verdict
NCT02652091 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 146 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess adherence and persistence to BETASERON therapy in patients who are using the BETACONNECT auto-injector device (BETACONNECT device). The secondary objective of this study is to assess patient-reported satisfaction with the BETACONNECT device.
Interventions
- DRUG Interferon beta-1b (Betaseron, BAY86-5046)
- DEVICE BETACONNECT device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2016-02-05 |
| Est. Completion | 2017-09-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02652091
The ClinicalTrials.gov registry entry for NCT02652091 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Interferon beta-1b (Betaseron, BAY86-5046) is the first listed.
NCT02652091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02652091 about?
NCT02652091 is a clinical study titled "Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction". The primary objective of this study is to assess adherence and persistence to BETASERON therapy in patients who are using the BETACONNECT auto-injector device (BETACONNECT device). The secondary objective of this study is to assess patient-reported satisfaction with the BETACONNECT device.
What is the current status of trial NCT02652091?
This trial is currently completed. The enrollment target is 146 participants. The study started on 2016-02-05. Estimated completion is 2017-09-13.
What interventions are being tested in trial NCT02652091?
The interventions under investigation include: Interferon beta-1b (Betaseron, BAY86-5046) (DRUG), BETACONNECT device (DEVICE).
Who is sponsoring clinical trial NCT02652091?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.